Does ADO-TRASTUZUMAB EMTANSINE Cause Second primary malignancy? 13 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Second primary malignancy have been filed in association with ADO-TRASTUZUMAB EMTANSINE. This represents 0.2% of all adverse event reports for ADO-TRASTUZUMAB EMTANSINE.
13
Reports of Second primary malignancy with ADO-TRASTUZUMAB EMTANSINE
0.2%
of all ADO-TRASTUZUMAB EMTANSINE reports
1
Deaths
2
Hospitalizations
How Dangerous Is Second primary malignancy From ADO-TRASTUZUMAB EMTANSINE?
Of the 13 reports, 1 (7.7%) resulted in death, 2 (15.4%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ADO-TRASTUZUMAB EMTANSINE. However, 13 reports have been filed with the FAERS database.
What Other Side Effects Does ADO-TRASTUZUMAB EMTANSINE Cause?
Nausea (780)
Fatigue (774)
Disease progression (750)
Diarrhoea (654)
Off label use (630)
Thrombocytopenia (519)
Death (509)
Neuropathy peripheral (506)
Headache (465)
Platelet count decreased (453)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which ADO-TRASTUZUMAB EMTANSINE Alternatives Have Lower Second primary malignancy Risk?
ADO-TRASTUZUMAB EMTANSINE vs ADRIAMYCIN
ADO-TRASTUZUMAB EMTANSINE vs ADUCANUMAB
ADO-TRASTUZUMAB EMTANSINE vs ADUCANUMAB-AVWA
ADO-TRASTUZUMAB EMTANSINE vs ADVAIR
ADO-TRASTUZUMAB EMTANSINE vs ADVAIR HFA